Lucid Capital Markets initiated coverage of Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) with a Buy rating and a price target of $8.00, implying 84% upside from the stock’s last close of $4.34.
The analyst cited Insight Molecular’s decentralized testing model as a structural shift in hospital diagnostics, where local labs use Bio-Rad Droplet Digital PCR instruments to run complex tests in-house rather than outsourcing to central laboratories. This approach delivers same-day or next-day results, preserves reimbursement economics for hospitals, and integrates into existing workflows. The firm expects adoption to accelerate among large hospital labs.
Insight Molecular reported a second-quarter 2026 adjusted loss of $0.23 per share, beating the consensus estimate of a $0.24 loss but missing revenue expectations by 49%, with reported revenue of $240,000 versus a forecast of $470,850. The company’s stock has gained 68% over the past year, and InvestingPro’s Fair Value analysis labels it undervalued at current levels.
Needham reiterated its Buy rating for Immunodiagnostics following a webinar featuring a cardiologist from Loyola University Medical Center, which highlighted the growing use of donor-derived cell-free DNA testing in heart transplant patients.
